TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30653847

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.3 mg starting dose, escalating to 3.0 mg or maximum tolerated dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28173938

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 70
Study: 26320489

Group type: EXPERIMENTAL
Intervention: Dose-dense cisplatin plus fluorouracil following selective radiotherapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Traditional cisplatin plus fluorouracil following selective radiotherapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dose-dense cisplatin plus fluorouracil following selective radiotherapy (subgroup analysis)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Traditional cisplatin plus fluorouracil following selective radiotherapy (subgroup analysis)
Number of subjects: 103
Study: 23585663

Group type: EXPERIMENTAL
Intervention: VRS-317 (0.05, 0.10, 0.20, 0.40, and 0.80 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VRS-317 (0.80 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: VRS-317
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21715702

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.25 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 19657872

Group type: EXPERIMENTAL
Intervention: Teaching Kids to Cope with Anger (TKC‐A)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 179
Study: 16706112

Group type: EXPERIMENTAL
Intervention: Health education for 6 months
Number of subjects: 82
Study: 15562167

Group type: EXPERIMENTAL
Intervention: Monophasic high voltage stimulation (MHVS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 14
Study: 11010838

Group type: EXPERIMENTAL
Intervention: cpts-248/404 vaccine
Number of subjects: 114
Study: 26630719

Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ketoprofen 37.5 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ketoprofen 12.5 mg and Ketoprofen 37.5 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 8119068

Group type: EXPERIMENTAL
Intervention: Three different levels of dietary protein and phosphorus intake with two levels of blood pressure control
Number of subjects: 840

Group type: COMPARATOR
Intervention: Referral by personal physician
Number of subjects: 840

Group type: COMPARATOR
Intervention: Self-referral after hearing about the trial from newspapers
Number of subjects: 840

Group type: COMPARATOR
Intervention: Self-referral after hearing about the trial from television
Number of subjects: 840

Group type: COMPARATOR
Intervention: Review of medical records from defined patient populations
Number of subjects: 840

Group type: COMPARATOR
Intervention: Calling a toll-free (800) telephone number
Number of subjects: 840
Study: 2851626

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol and Enalapril
Number of subjects: 0
Study: 30992044

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 60
Study: 28528211

Group type: EXPERIMENTAL
Intervention: Intravenous Levetiracetam (LEV)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intravenous Phenytoin (DPH)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both LEV and DPH
Number of subjects: 115

Group type: COMPARATOR
Intervention: Adverse events with DPH
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Adverse events with LEV
Number of subjects: 115
Study: 25453536

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23166037

Group type: EXPERIMENTAL
Intervention: SSRIs during pregnancy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 21974796

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (50 mg.kg(‐1) in 100 ml saline over 10 min followed by a continuous infusion of 20 mg.kg.h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 40
Study: 18096708

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Empirical rules
Number of subjects: 79
Study: 21967953

Group type: EXPERIMENTAL
Intervention: Headgear or biteplane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 0
Study: 16229231

Group type: EXPERIMENTAL
Intervention: Neonatal BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no BCG revaccination)
Number of subjects: 0
Study: 11966500

Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate (150 mg) with calcium (1 g) and vitamin D (800 IU)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Calcium (1 g) and vitamin D (800 IU) with placebo
Number of subjects: 94
Study: 9673745

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg (up to 80 mg daily)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Simvastatin 10 mg (up to 40 mg daily +/− cholestyramine 4 g daily in 84% of cases)
Number of subjects: 136
Study: 8083103

Group type: EXPERIMENTAL
Intervention: Postoperative radiation (40 Gy in 16 fractions to the whole breast, followed by a boost of 12.5 Gy in five fractions to the primary site)
Number of subjects: 837

Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 837
Study: 2589654

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine (400 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine (300 mg)
Number of subjects: 30
Study: 1068569

Group type: EXPERIMENTAL
Intervention: Topically applied amine fluoride (Elmex fluid and Elmex toothpaste)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30402992

Group type: EXPERIMENTAL
Intervention: Pilates exercise programme
Number of subjects: 22
Study: 29776437

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 plus trimetazidine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 27021239

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24667535

Group type: EXPERIMENTAL
Intervention: Controlled exposure to air pollutants (dilute diesel exhaust, wood smoke, ozone, concentrated ambient particles, engineered carbon nanoparticles, high ambient levels of air pollution)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Controlled exposure to air pollutants
Number of subjects: 282
Study: 22085207

Group type: EXPERIMENTAL
Intervention: One-to-one communication training with direct oral feedback from the standardized patient
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer role-playing and mutual feedback
Number of subjects: 0
Study: 19287109

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 50
Study: 17898458

Group type: EXPERIMENTAL
Intervention: 5.4 g CLA-triacylglycerol (3.4 g as CLA) daily for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10.8 g CLA-triacylglycerol (6.8 g as CLA) daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (10.8 g safflower oil) daily for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.4 g CLA-triacylglycerol (3.4 g as CLA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10.8 g CLA-triacylglycerol (6.8 g as CLA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (10.8 g safflower oil)
Number of subjects: 60
Study: 15041522

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11444174

Group type: EXPERIMENTAL
Intervention: Glicocorticoids
Number of subjects: 0
Study: 9443112

Group type: EXPERIMENTAL
Intervention: Formula with 18 g/l of protein (F18)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Formula with 13 g/l of protein (F13)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Formula with 15 g/l of protein (F15)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Breast milk only
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mixed-fed (breast milk and formula)
Number of subjects: 71
Study: 7987965

Group type: EXPERIMENTAL
Intervention: 3% LMCS gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% LMCS gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% LMCS gum (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% glucose solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugared caramel
Number of subjects: 0
Study: 2660445

Group type: EXPERIMENTAL
Intervention: Cardiospermum ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ointment base only (placebo)
Number of subjects: 0
Study: 29421164

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 71
Study: 28195874

Group type: EXPERIMENTAL
Intervention: HCV-PERF
Number of subjects: 309

Group type: COMPARATOR
Intervention: Didactic control
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 309
Study: 25628269

Group type: EXPERIMENTAL
Intervention: DAILIES TOTAL1 (DT1)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Clariti 1Day (C1D)
Number of subjects: 104

Group type: COMPARATOR
Intervention: 1‐DAY ACUVUE TruEye (AVTE)
Number of subjects: 104
Study: 21716127

Group type: EXPERIMENTAL
Intervention: Beclomethasone nasal spray
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo saline nasal spray
Number of subjects: 19
Study: 21038998

Group type: EXPERIMENTAL
Intervention: Correlated sequences of tasks and mappings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single task sequence or single mapping sequence
Number of subjects: 0
Study: 18160462

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg/d for 2 years (after 1 year of treatment)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg/d for 2 years
Number of subjects: 245
Study: 16372331

Group type: EXPERIMENTAL
Intervention: Parenteral estrogen or total androgen ablation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 153
Study: 11994904

Group type: EXPERIMENTAL
Intervention: Metformin 2.5 g/day plus rosiglitazone 2 mg bd
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Metformin 2.5 g/day plus rosiglitazone 4 mg bd
Number of subjects: 116

Group type: COMPARATOR
Intervention: Metformin 2.5 g/day plus placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 116
Study: 9894935

Group type: EXPERIMENTAL
Intervention: Clinician assessment of corneal scarring
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Photograph-reader assessment of corneal scarring
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Comparison of photograph-reader assessments with clinician results
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Assessment of agreement when Vogt's striae and corneal nerves were observed
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Assessment of agreement when corneal staining was not observed
Number of subjects: 1209
Study: 8545750

Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 2179393

Group type: EXPERIMENTAL
Intervention: Cyclofenil treatment
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Overall pregnancy rates by cause of infertility
Number of subjects: 213
Study: 6153233

Group type: EXPERIMENTAL
Intervention: Anorectic preparation ('Trimolets'; 85 mg phenylpropanolamine per capsule)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Decongestant preparation ('Contac 500'; 50 mg phenylpropanolamine per capsule)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 71
Study: 31841646

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 29040891

Group type: EXPERIMENTAL
Intervention: Monitor+Accept
Number of subjects: 153

Group type: COMPARATOR
Intervention: Monitor Only
Number of subjects: 153

Group type: COMPARATOR
Intervention: Coping control
Number of subjects: 153
Study: 26857727

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment treatment for nasal carriers of S. aureus
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Treated carriers
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Untreated carriers
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Non-carriers
Number of subjects: 568
Study: 25625809

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with saline (NI-S)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with xylitol (NI-X)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 75
Study: 23724544

Group type: EXPERIMENTAL
Intervention: gel with 4,500 ppm F + 5% TMP (4,500 5% TMP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gel with 9,000 ppm F (9,000)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gel with 12,300 ppm F (12,300)
Number of subjects: 12

Group type: COMPARATOR
Intervention: gel without F or TMP (placebo)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: gel with 4,500 ppm F (4,500)
Number of subjects: 12
Study: 20950383

Group type: EXPERIMENTAL
Intervention: Standard PREPARE programme
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pedometer group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pooled study sample
Number of subjects: 74
Study: 18199105

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg for 4 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg
Number of subjects: 40
Study: 16472525

Group type: EXPERIMENTAL
Intervention: Sensorimotor (SENSO) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heavy resistance (HR) training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 14684762

Group type: EXPERIMENTAL
Intervention: 10 g of flaxseed
Number of subjects: 16

Group type: COMPARATOR
Intervention: 28 g of wheat bran
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 g of flaxseed plus 28 g of wheat bran
Number of subjects: 16

Group type: COMPARATOR
Intervention: No flaxseed or wheat bran
Number of subjects: 16
Study: 10953898

Group type: EXPERIMENTAL
Intervention: Prescription plus mailed booklet
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: Prescription only
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1142
Study: 9437624

Group type: EXPERIMENTAL
Intervention: Naltrexone plus brief drug counseling
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (probation plus counseling alone)
Number of subjects: 51
Study: 8499152

Group type: EXPERIMENTAL
Intervention: Primary induction chemotherapy with a limit of 25% tumour cell mass (TCM) reduction to separate responders from non-responders
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Histological grading of myeloma cells, TCM, and platelet counts
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Pretreatment platelets of < or = 150,000 and/or poorly differentiated myeloma cell morphology
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Patients lacking both risk factors (platelets < or = 150,000 and poorly differentiated morphology)
Number of subjects: 320
Study: 3320720

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 27
Study: 29217669

Group type: EXPERIMENTAL
Intervention: 930 mg choline/d
Number of subjects: 26

Group type: COMPARATOR
Intervention: 480 mg choline/d
Number of subjects: 26
Study: 26989833

Group type: EXPERIMENTAL
Intervention: self-focus of attention
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: self-focus of attention with a negative mood induction
Number of subjects: 173

Group type: COMPARATOR
Intervention: external focus of attention
Number of subjects: 173
Study: 24913210

Group type: EXPERIMENTAL
Intervention: Playing the serious game GeriatriX
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (usual geriatric education)
Number of subjects: 134
Study: 22339275

Group type: EXPERIMENTAL
Intervention: PSUNC message exposure
Number of subjects: 394
Study: 20555312

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 25 mg equiv.
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 50 mg equiv.
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg equiv.
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (all doses)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study: 18690985

Group type: EXPERIMENTAL
Intervention: Ceftriaxone-Vancomycin fixed-dose combination 1.5 g B.D. for 3-10 days (Group A, n=106)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ceftriaxone-Vancomycin fixed-dose combination 3.0 g B.D. for 3-10 days (Group B, n=199)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ceftriaxone-Vancomycin fixed-dose combination
Number of subjects: 305
Study: 15853114

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20% carbamide peroxide with fluoride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 24
Study: 12379544

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 2 x 400 mg for 4 days and topical gentamicin and polymyxin
Number of subjects: 546

Group type: COMPARATOR
Intervention: Intravenous and topical placebo
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin and topical antibiotics
Number of subjects: 546
Study: 9844953

Group type: EXPERIMENTAL
Intervention: Bech-Rafaelsen Melancholia Scale (BRMES)
Number of subjects: 132
Study: 8092089

Group type: EXPERIMENTAL
Intervention: 50 g raw potato starch (54% RS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 g pregelatinized starch (0% RS)
Number of subjects: 10
Study: 2817915

Group type: EXPERIMENTAL
Intervention: Kenalog creams 0.025%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aristocort creams 0.025%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aristocort ointments 0.1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aristocort creams 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hytone cream 1.0%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synalar creams 0.01%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topicort creams 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vallisone creams 0.1%
Number of subjects: 0
Study: 1215862

Group type: EXPERIMENTAL
Intervention: Inhalation of orciprenaline aerosol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Spraying the oropharynx with orciprenaline aerosol
Number of subjects: 12
Study: 7406656

Group type: EXPERIMENTAL
Intervention: Pemoline (Cylert)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin) hydrochloride
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30832581

Group type: EXPERIMENTAL
Intervention: CarFreeMe intervention, an intensive program delivered by a trained health professional, covering seven modules addressing practical and emotional needs relevant to driving cessation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatment (control group).
Number of subjects: 0
Study: 28097926

Group type: EXPERIMENTAL
Intervention: Minimally supervised home exercise program (8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care group (n = 14)
Number of subjects: 30
Study: 24259406

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 23350957

Group type: EXPERIMENTAL
Intervention: Continuous cycling at 70% of maximum oxygen uptake for 20 minutes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sprint interval cycling (four 30-second bouts with 4.5 minutes recovery)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 9
Study: 21561483

Group type: EXPERIMENTAL
Intervention: Straumann bone ceramic(®) (SBC) with a collagen barrier membrane (Bio‐Gide(®))
Number of subjects: 27

Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral with the same barrier
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both treatments (SBC and deproteinized bovine bone)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SBC
Number of subjects: 27
Study: 19694333

Group type: EXPERIMENTAL
Intervention: Cisplatin plus fluorouracil with pelvic radiotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cisplatin with pelvic radiotherapy
Number of subjects: 20
Study: 17725736

Group type: EXPERIMENTAL
Intervention: Unmodified RBCs (UN‐RBCs, n = 18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Leukoreduced RBCs (LR‐RBCs, n = 17)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Unmodified RBCs (UN‐RBCs)
Number of subjects: 35